Regimen simplification and medication adherence: Fixed-dose versus loose-dose combination therapy for type 2 diabetes

被引:32
|
作者
Boehm, Anna-Katharina [1 ]
Schneider, Udo [2 ]
Aberle, Jens [3 ]
Stargardt, Tom [1 ]
机构
[1] Univ Hamburg, Hamburg Ctr Hlth Econ, Hamburg, Germany
[2] Techniker Krankenkasse, Hamburg, Germany
[3] Univ Hosp Hamburg Eppendorf, Univ Obes Ctr Hamburg, Dept Endocrinol & Diabetol, Hamburg, Germany
来源
PLOS ONE | 2021年 / 16卷 / 05期
关键词
DUAL THERAPY; MONOTHERAPY; NONADHERENCE; PERSISTENCE; COPAYMENTS; IMPACT;
D O I
10.1371/journal.pone.0250993
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background Suboptimal patient adherence to pharmacological therapy of type 2 diabetes may be due in part to pill burden. One way to reduce pill burden in patients who need multiple medications is to use fixed-dose combinations. Our study aimed to compare the effects of fixed-dose combination versus loose-dose combination therapy on medication adherence and persistence, health care utilization, therapeutic safety, morbidities, and treatment modification in patients with type 2 diabetes over three years. Methods Using administrative data, we conducted a retrospective controlled cohort study comparing type 2 diabetes patients who switched from monotherapy to either a fixed-dose combination or a loose-dose combination. Adherence was assessed as the primary endpoint and calculated as the proportion of days covered with medication. After using entropy balancing to eliminate differences in observable baseline characteristics between the two groups, we applied difference-in-difference estimators for each outcome to account for time-invariant unobservable heterogeneity. Results Of the 990 type 2 diabetes patients included in our analysis, 756 were taking a fixed-dose combination and 234 were taking a loose-dose combination. We observed a statistically significantly higher change in adherence (year one: 0.22, p<0.001, year two: 0.25, p<0.001, and year three: 0.29, p<0.001) as well as higher persistence and a smaller change in the number of drug prescriptions in each of the three years in the fixed-dose combination group compared to the loose-dose combination group. The differences were most pronounced in patients who were poorly adherent, had a high pill burden, or did not have a severe concomitant disease. Conclusion Our results indicate that taking a fixed-dose combination can lead to a significant improvement in adherence to pharmacological therapy of type 2 diabetes compared to a loose-dose combination. In particular, these findings suggest that reducing pill burden may improve disease management among patients with more complex medication demand and patients who have demonstrated poor medication adherence.
引用
收藏
页数:17
相关论文
共 50 条
  • [21] Fixed-dose combination therapy for psoriasis
    Guenther, LC
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2004, 5 (02) : 71 - 77
  • [22] Fixed-Dose Combination Therapy in HypertensionPros
    Stefano Taddei
    High Blood Pressure & Cardiovascular Prevention, 2012, 19 (2) : 55 - 57
  • [23] Fixed-Dose Combination Therapy for Psoriasis
    Lyn C. Guenther
    American Journal of Clinical Dermatology, 2004, 5 : 71 - 77
  • [24] Compliance and fixed-dose combination therapy
    Sripal Bangalore
    Anupama Shahane
    Sanobar Parkar
    Franz H. Messerli
    Current Hypertension Reports, 2007, 9 : 184 - 189
  • [25] Fixed-Dose Combination Therapy in HypertensionCons
    Fabio Angeli
    Gianpaolo Reboldi
    Giovanni Mazzotta
    Marta Garofoli
    Elisa Ramundo
    Cristina Poltronieri
    Paolo Verdecchia
    High Blood Pressure & Cardiovascular Prevention, 2012, 19 (2) : 51 - 54
  • [26] Compliance and fixed-dose combination therapy
    Bangalore, Sripal
    Shahane, Anupama
    Parkar, Sanobar
    Messerli, Franz H.
    CURRENT HYPERTENSION REPORTS, 2007, 9 (03) : 184 - 189
  • [27] Empagliflozin/metformin fixed-dose combination: a review in patients with type 2 diabetes
    Hu, Jingbo
    Zou, Ping
    Zhang, Shuo
    Zhou, Minzhi
    Tan, Xueying
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (18) : 2471 - 2477
  • [28] Fixed-dose combination of ertugliflozin and metformin hydrochloride for the treatment of type 2 diabetes
    Frias, Juan Pablo
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2019, 14 (02) : 75 - 83
  • [29] Fixed-dose combinations in type 2 diabetes - role of the canagliflozin metformin combination
    Fleming, Joshua W.
    Fleming, Laurie W.
    Davis, Courtney S.
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2015, 8 : 287 - 294
  • [30] Acarbose plus metformin fixed-dose combination in the management of type 2 diabetes
    Joshi, Shashank R.
    Ramachandran, Ambady
    Chadha, Manoj
    Chatterjee, Sudip
    Rathod, Rahul
    Kalra, Sanjay
    EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (11) : 1611 - 1620